Ameloblastoma, a benign yet aggressive odontogenic tumor known for its recurrence and the severe morbidity from radical surgeries, may benefit from advancements in targeted therapy. We present a case of a 15-year-old girl with ameloblastoma successfully treated with targeted therapy and review the literature with this question: Is anti-MAPK targeted therapy safe and effective for treating ameloblastoma? This systematic review was registered in PROSPERO, adhered to PRISMA guidelines, and searched multiple databases up to December 2023, identifying 13 relevant studies out of 647 records, covering 23 patients treated with MAPK inhibitor therapies. The results were promising as nearly all patients showed a positive treatment response, with four achieving complete radiological remission and others showing substantial reductions in primary, recurrent, and metastatic ameloblastoma sizes. Side effects were mostly mild to moderate. This study presents anti-MAPK therapy as a significant shift from invasive surgical treatments, potentially enhancing life quality and clinical outcomes by offering a less invasive yet effective treatment alternative. This approach could signify a breakthrough in managing this challenging tumor, emphasizing the need for further research into molecular-targeted therapies.
成釉细胞瘤是一种良性但具有侵袭性的牙源性肿瘤，以易复发及根治性手术导致严重并发症而著称，靶向治疗的进展可能为其治疗带来新希望。本文报道一例15岁女性成釉细胞瘤患者经靶向治疗成功的案例，并围绕“抗MAPK靶向治疗对成釉细胞瘤是否安全有效”这一问题进行文献综述。本系统评价已在PROSPERO平台注册，遵循PRISMA指南，检索截至2023年12月的多个数据库，从647条记录中筛选出13项相关研究，共涵盖23例接受MAPK抑制剂治疗的患者。研究结果令人鼓舞：几乎所有患者均呈现积极治疗反应，其中4例实现影像学完全缓解，其余患者的原发、复发及转移性成釉细胞瘤体积均显著缩小。不良反应多为轻至中度。本研究提出抗MAPK疗法标志着从侵袭性手术治疗模式的重要转变，通过提供创伤更小且有效的替代方案，有望提升患者生活质量和临床疗效。该治疗策略可能成为应对这一棘手肿瘤的突破性进展，凸显了进一步开展分子靶向治疗研究的必要性。
Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review
肿瘤(癌症)患者之家